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INTRODUCTION 
In this issue, Seo et al, on behalf of all participants in the COACT (Catholic University 
of Koreaepercutaneous coronary intervention) registry, report that after placement of 
a drug-eluting stent in patients with coronary artery disease (CAD) and well controlled 
low-density lipoprotein (LDL-C) serum levels below 100 mg/dl, the high-density lipo-
protein (HDL-C) serum concentrations remain a significant prognostic indicator of 
future cardiovascular events.1 The authors dichotomised the patient cohort according 
to HDL-C levels (40 mg/dl for men or 50 mg/dl for women) and compared major ad-
verse cardiovascular event rates (MACE). Patients with low HDL-C levels (<40 mg/dl 
for men or <50 mg/dl for women) had a 40% higher rate of major adverse cardiac 
events (MACE), including all-cause death, non-fatal myocardial infarction and target 
vessel revascularisation (adjusted HR 1.404, 95% CI 1.111 to 1.774, p¼0.004). Their 
well conducted study confirms the results of a post-hoc analysis of the Treating to 
New Targets trial, in which a 39% lower risk for cardiovascular events was observed 
for patients with stable CAD in the highest versus lowest HDL-C quintiledeven under 
statin therapy and LDL-C levels <100 mg/dl.2 In contrast to Treating to New Targets, 
however, Seo et al assessed the risk reduction in a postinterventional CAD cohort 
recruited for a national registry, thus reflecting a more ‘real-world’ scenario. However, 
there are also some caveats in a registry as compared to a prospective randomised 
trial: patients with low HDL-C were more likely to present with acute coronary syn-
drome (ACS), had a 10.3% higher prevalence of diabetes mellitus, and a 5.8% higher 
prevalence of arterial hypertension (see their table 1). To exclude that the higher 
event rate in the low HDL-C group was primarily driven by the higher prevalence of 
ACS and established risk factors, the authors used a propensity score matching to 
balance for clinical covariates. It is reassuring that the higher MACE rate and target 
vessel revascularisation associated with low HDL-C did not differ significantly be-
tween the total patient population and the propensitymatched population.  
 
HDL AS A PROGNOSTIC INDICATOR 
The prognostic relevance of high HDL-C plasma levels is well established in the 
medical literature. Since the 1980s when the Framingham study first demonstrated a 
reduced risk for coronary heart disease among subjects with HDL-C levels above the 
average range of 40e60 mg/dl,3 4 several large cohort studies found HDL to be a 
strong independent predictor of lower CAD risk.4-7 In consequence, both the ESC and 
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the US National Cholesterol Education Program recognised HDL as an independent 
risk marker and recommended screening for low HDL levels as part of primary and 
secondary prevention treatment.8 9 An increase in HDL-C by 1 mg/dl is calculated to 
be associated with a 2% lower risk of CAD in men and a 3% lower risk in women.2 
Hence low HDL-C levels have become a new therapeutic targetdparticularly because 
of studies indicating that a reversal of the atherosclerotic disease process could be 
achieved by some interventions, increasing HDL-C levels 10 11 and enhancing the 
HDL-C mediated reverse cholesterol transport from the foam cells in the arterial wall 
to the liver (see Natarajan et al for a review12). It is well established that in the setting 
of high LDL-C levels, higher HDL levels are associated with protection from progres-
sion of atherosclerosis.13 However, it is still unclear whether HDL-C retains its prog-
nostic significance even under optimal control of LDL-C. In recent years, evidence is 
accumulating that even when there are very low LDL-C concentrations after intense 
lipid-lowering therapy in patients with coronary disease, lower HDL-C remains inde-
pendently associated with increased cardiovascular risk.2 14 The current study adds 
to this body of evidence.  
 
HDL LEVELS AND FUNCTION 
The simple strategy of pharmacologically increasing HDL-C concentration in the cir-
culation may, however, not be a universal solution. Beyond pure quantity, HDL quali-
tydthat is, the functional properties of HDLdhave been shown to play a key role in the 
atheroprotective effects. HDL has been proposed to protect from atherosclerosis by 
promotion of macrophage cholesterol effluxdthat is, reverse cholesterol transportdbut 
also by stimulation of endothelial cell nitric oxide production and endothelial repair as 
well as anti-inflammatory and anti-oxidant effects.15-17 However, these studies have 
largely been performed using reconstituted HDL or HDL isolated from healthy sub-
jects. In the recent ILLUMINATE study, an increased rate of cardiovascular events 
was observed despite a substantial increase of the HDL cholesterol plasma levels in 
patients treated with torcetrapib in addition to standard statin therapy. This raises the 
question of whether HDL from patients with coronary disease retains vasoprotective 
properties.18 Importantly, several recent studies have suggested that the vascular 
effects of HDL can be highly heterogeneous. A reduced macrophage cholesterol ef-
flux capacity of apoB-depleted serum was associated with an increased risk of coro-
nary disease in a caseecontrol study.19 In several recent studies it was observed that 
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HDL from patients with coronary disease or diabetes, in contrast to HDL from healthy 
subjects, had lost the capacity to stimulate endothelial nitric oxide production, result-
ing in a loss of anti-inflammatory properties of the lipoprotein.20-22 The molecular 
mechanisms underlying this ‘HDL dysfunction’ are still incompletely understood, but 
likely involve oxidative modification of the lipoprotein.22 These studies therefore sug-
gest that HDL-targeted therapies should not only increase HDL levels, but should 
also promote a vasoprotective on-treatment HDL in order to truly exert vasoprotective 
effects.  
 
LIPID CONTROL AND/OR CORONARY INTERVENTION? 
Interventional cardiologists are sometimes inclined to believe that the effective me-
chanical treatment of a high-grade coronary stenosis by implantation of a latest tech-
nology drug eluting stent solves the patient’s problem. While the beneficial prognostic 
impact of percutaneous coronary interventions (PCI) is well established in ACS, it is 
highly debated among patients presenting with stable CAD. According to the COUR-
AGE trial, optimal medical therapy may be an alternative strategy in stable CAD, with 
the same clinical outcome with respect to prognosis,23 at least for patients that have 
clinical characteristics similar to patients randomised in the trial and who do not have 
extensive cardiac ischaemia. What COURAGE and several other studies focusing on 
optimal secondary prevention by use of b blockers, statins and platetelet inhibitors 
confirmed, is the paramount clinical importance of controlling cardiovascular risk fac-
tors. Even in ACS, an improved microcirculation immediately after PCI and a reduc-
tion in MACE achieved by aggressive LDL-C lowering has been reported.24 25 It is still 
unclear whether an initial conservative strategy in patients with stable CAD and opti-
mal medical therapy with LDL-C <70 mg/dl and pharmacological HDL-C increases 
>60 mg/dl may be superior to PCI plus usual care. The study by Seo et al indicates 
that targeting HDL post-PCI could further decrease adverse event rates. However, 
we are still lacking prospective randomised clinical studies in patients post-PCI on the 
additional benefit of pharmacologically increasing HDL-C. Until then we should follow 
the guidance of the recent position paper of the European Atherosclerosis Society 
Consensus Panel, which proposed that “therapeutic targeting of elevated triglyc-
erides (≥1.7 mmol/l or 150 mg/dl), ... and/or low HDL-C (<1.0 mmol/l or 40 mg/dl) 
may provide further benefit. The first step should be lifestyle interventions together 
with consideration of compliance with pharmacotherapy and secondary causes of 
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dyslipidaemia. If inadequately corrected, adding niacin or a fibrate, or intensifying 
LDL-C lowering therapy may be considered.”26 In the study by Seo et al, the LDL-C 
target of LDL-C <70 mg was reached in 52.6% of all patients, which is more than in 
the last EUROASPIRE III study, where only 30.6% of patients on lipid-lowering medi-
cation achieved the target values for total cholesterol.27 A recent study by Borden et 
al confirmed that less than half of the patients undergoing PCI in the USA receive 
optimal medical therapy before PCI, with little change after the publication of COUR-
AGE.28 One can only reiterate the authors’ conclusion that “multidisciplinary teams 
could use ... this ‘teachable moment’ of an invasive procedure to impart to patients 
the importance of medication adherence, and engage the patient in a program that 
supports the transition of care so that important medications are implemented.”28 We 
are not lacking the evidence for effective risk control; the lack is in its clinical imple-
mentation. The study by Seo et al confirms that improved LDL-C control, and in the 
future, hopefully, HDL therapy, will result in improved outcomes for our patients.  
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